UK Biobank released the final tranche of metabolomics data covering 249 blood metabolites for roughly 500,000 participants, creating the largest public metabolomics resource to date. The dataset links metabolite profiles with UK Biobank’s existing genotypes, proteomics and imaging, enabling large‑scale multiomics discovery of biomarkers, disease pathways and therapeutic targets. Investigators and industry teams will use the atlas to power population‑scale association studies, polygenic risk refinement and drug target validation across cardiometabolic, neurodegenerative and oncologic indications.